These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 19122466

  • 1. Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience.
    Ailawadhi S, Derby L, Natarajan R, Fetterly G, Reid M, Ramnath N.
    Oncology; 2009; 76(2):85-90. PubMed ID: 19122466
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
    Boyer M, Horwood K, Pavlakis N, De Souza P, Millward M, Stein B, Johnston M, Abell F, Rischin D.
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):248-54. PubMed ID: 22898114
    [Abstract] [Full Text] [Related]

  • 5. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M.
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [Abstract] [Full Text] [Related]

  • 6. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.
    Faehling M, Eckert R, Kuom S, Kamp T, Stoiber KM, Schumann C.
    Oncology; 2010 Jan; 78(3-4):249-58. PubMed ID: 20523085
    [Abstract] [Full Text] [Related]

  • 7. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
    Tiseo M, Gridelli C, Cascinu S, Crinò L, Piantedosi FV, Grossi F, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A.
    Lung Cancer; 2009 May; 64(2):199-206. PubMed ID: 18951651
    [Abstract] [Full Text] [Related]

  • 8. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
    Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, Tryfonidis K, Kotsakis A, Vamvakas L, Vardakis N, Georgoulias V.
    Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Erlotinib in previously treated non-small-cell lung cancer.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group.
    N Engl J Med; 2005 Jul 14; 353(2):123-32. PubMed ID: 16014882
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
    Zhou S, Ren S, Yan L, Zhang L, Tang L, Zhang J, Zhou C.
    Respirology; 2009 Jul 14; 14(5):709-15. PubMed ID: 19659649
    [Abstract] [Full Text] [Related]

  • 15. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA.
    J Clin Oncol; 2008 May 10; 26(14):2350-7. PubMed ID: 18467727
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA, TRIBUTE Investigator Group.
    J Clin Oncol; 2005 Sep 01; 23(25):5892-9. PubMed ID: 16043829
    [Abstract] [Full Text] [Related]

  • 18. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
    Heigener DF, Wu YL, van Zandwijk N, Mali P, Horwood K, Reck M.
    Lung Cancer; 2011 Nov 01; 74(2):274-9. PubMed ID: 21439671
    [Abstract] [Full Text] [Related]

  • 19. Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
    Popat S, Barbachano Y, Ashley S, Norton A, O'Brien M.
    Lung Cancer; 2008 Feb 01; 59(2):227-31. PubMed ID: 17920156
    [Abstract] [Full Text] [Related]

  • 20. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment.
    Wang YS, Miao LY, Liu L, Cai HR, Ding JJ, Ren SX, Zhou CC, Schmid-Bindert G.
    Chin Med J (Engl); 2013 Oct 01; 126(20):3931-5. PubMed ID: 24157160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.